Coya Therapeutics Files 8-K Report
Ticker: COYA · Form: 8-K · Filed: Jul 1, 2025 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Coya Therapeutics filed an 8-K on 6/30/25 for 'Other Events'.
AI Summary
On June 30, 2025, Coya Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company's principal executive offices are located at 5850 San Felipe St., Suite 500, Houston, Texas 77057.
Why It Matters
This 8-K filing signals that Coya Therapeutics has reported a material event, requiring immediate disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K disclosure of 'Other Events' without immediate indication of significant financial or operational changes.
Key Numbers
- 001-41583 — Commission File Number (Identifies Coya Therapeutics' filing with the SEC.)
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
- 5850 San Felipe St., Suite 500, Houston, Texas 77057 (location) — Address of Principal Executive Offices
- Delaware (location) — State of Incorporation
- 001-41583 (other) — Commission File Number
FAQ
What specific event triggered this 8-K filing?
The filing indicates 'Other Events' as the item information, but does not specify the exact event in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on June 30, 2025.
What is Coya Therapeutics' principal executive office address?
The principal executive offices are located at 5850 San Felipe St., Suite 500, Houston, Texas 77057.
In which state was Coya Therapeutics incorporated?
Coya Therapeutics, Inc. was incorporated in Delaware.
What is the company's telephone number?
The registrant's telephone number, including area code, is 800 587-8170.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Coya Therapeutics, Inc. (COYA).